| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CNSA2; SH3P4; EEN-B1; SH3D2A |
| WB Predicted band size | 40 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SH3GL2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SH3GL2抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*SH3GL2 modulates synaptic vesicle endocytosis and exocytosis in neuronal cells*
**作者**：Ringstad N, et al.
**摘要**：该研究利用SH3GL2抗体进行免疫印迹和免疫荧光染色，发现SH3GL2通过与动力蛋白(Dynamin)相互作用调控突触小泡的回收，影响神经递质释放和神经元通讯。
2. **文献名称**：*SH3GL2 regulates EGFR endocytosis and downstream signaling in cancer progression*
**作者**：Szymkiewicz I, et al.
**摘要**：通过SH3GL2抗体的免疫共沉淀(Co-IP)和细胞定位分析，揭示SH3GL2在表皮生长因子受体(EGFR)内吞中的作用，其表达缺失加速肿瘤细胞增殖和迁移。
3. **文献名称**：*Loss of SH3GL2 promotes α-synuclein aggregation in Parkinson’s disease models*
**作者**：Tian JH, et al.
**摘要**：研究使用SH3GL2抗体检测其在帕金森病模型中的表达变化，发现SH3GL2缺失导致α-突触核蛋白异常聚集，提示其参与神经退行性病变的分子机制。
4. **文献名称**：*SH3GL2-mediated membrane curvature sensing in autophagy initiation*
**作者**：Kumar D, et al.
**摘要**：通过SH3GL2抗体的功能阻断实验，证实其通过感知膜曲率促进自噬体形成，影响细胞在营养胁迫下的存活能力。
这些研究均依赖SH3GL2抗体进行蛋白检测或功能研究，涵盖神经科学、肿瘤学及细胞自噬等领域，展示了该抗体在基础研究中的广泛应用。
The SH3GL2 antibody targets the SH3 domain-containing GRB2-like protein 2 (SH3GL2), also known as Endophilin-A1. a protein encoded by the *SH3GL2* gene. This protein belongs to the endophilin-A subfamily and plays a critical role in membrane dynamics, particularly in clathrin-mediated endocytosis. SH3GL2 facilitates vesicle formation by interacting with dynamin and other components of the endocytic machinery, contributing to synaptic vesicle recycling in neurons and receptor trafficking in non-neuronal cells. Its SH3 domain mediates protein-protein interactions, enabling recruitment of partners involved in membrane curvature and scission.
SH3GL2 is implicated in neurological disorders and cancer. In neurodegenerative diseases like Huntington’s disease, reduced SH3GL2 levels correlate with synaptic dysfunction. In cancer, SH3GL2 may act as a tumor suppressor, with downregulation observed in gliomas, breast, and prostate cancers. The SH3GL2 antibody is widely used in research to study these mechanisms via techniques like Western blotting, immunohistochemistry, and immunofluorescence. It helps assess protein expression, localization, and interactions in disease models. Commercial antibodies vary in specificity, with validation often performed using knockout controls or siRNA knockdown. Researchers prioritize antibodies with high affinity and minimal cross-reactivity to closely related isoforms (e.g., SH3GL1. SH3GL3) to ensure accurate experimental outcomes.
×
